Compare FRGT & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRGT | BDRX |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | Mexico | United Kingdom |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.0M |
| IPO Year | N/A | N/A |
| Metric | FRGT | BDRX |
|---|---|---|
| Price | $1.63 | $2.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 83.8K | ★ 461.1K |
| Earning Date | 02-16-2026 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,263,031.00 | N/A |
| Revenue This Year | $371.03 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.48 | $2.06 |
| 52 Week High | $69.80 | $92.00 |
| Indicator | FRGT | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 39.15 |
| Support Level | $1.51 | $2.06 |
| Resistance Level | $2.16 | $2.37 |
| Average True Range (ATR) | 0.19 | 0.17 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 15.95 | 36.60 |
Freight Technologies Inc is a technology company developing solutions to optimize and automate the supply chain process. Along with its subsidiary, Freight App, Inc, the group is focused on making shipping transparent and efficient. Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility, and simplicity for the once-complex process of international over-the-road (OTR) shipping. The company uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.